Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says
Executive Summary
FDA Commissioner Margaret Hamburg said that working within the current regulatory framework rather than seeking new statutory authority to address the development of drugs and accompanying diagnostic tests would be preferable to address personalized medicine questions at the agency
You may also be interested in...
Personalized Medicine Needs Personalized Advocacy To Advance, PhRMA Says
CEO Castellani says message has to be specifically tailored to payers, patient advocates and regulators.
FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed